SanaCurrents on Anika’s (ANIK) third-gen treatment for osteoarthritis
Anika Therapeutics Inc. (NASDAQ:ANIK) Probability Sentiment SUMMARY After a turbulent three years, Anika Therapeutics, Inc. [...]
SanaCurrents on Vaxcyte (PCVX) new pneumonia vaccine
Vaxcyte, Inc. (NASDAQ:PCVX) Probability Sentiment SUMMARY Vaccines once were considered poor performing units inside Big [...]
SanaCurrents’ speculative report on Aptinyx’s (APTX) phase II trial of NYX-2925 fibromyalgia
Aptinyx Inc. (NASDAQ:APTX) Probability Sentiment SUMMARY Aptinyx, Inc. (NASDAQ:APTX) listed four years ago on the [...]
SanaCurrents on Prometheus’ (RXDX) precision medicine approach in ulcerative colitis & Crohn’s disease
Prometheus Biosciences, Inc. (NASDAQ:RXDX) Probability Sentiment SUMMARY Early-stage investors continue to back new drugs for [...]
SanaCurrents on Rani’s (RANI) transformative RaniPill to deliver large molecule biologics
$RANI Probability Sentiment Needles. Who enjoys needles? No one. If someone claims indifference to regular [...]
SanaCurrents Portfolio Update: APLS files NDA, IMUX UC drug falters in phase II topline, plus VERA and ACET
Apellis Pharmaceuticals (NASDAQ:APLS) on June 1 submitted an NDA for its drug pegcetacoplan to be approved to treat geographic atrophy [...]
SanaCurrents on FDA decision for uniQure’s (QURE) gene therapy to treat hemophilia B
uniqure N.v. (NASDAQ:QURE) Probability Sentiment SUMMARY The inherited bleeding disorder hemophilia remains a lucrative rare [...]
SanaCurrents on Insmed’s (INSM) entry in pulmonary arterial hypertension (PAH)
Insmed, Inc. (NASDAQ:INSM) Probability Sentiment SUMMARY Pulmonary arterial hypertension (PAH) comprises a group of severe [...]